Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Weight Loss Drugs Market’s Growth Trajectory From 2025 To 2034?
The market size for weight loss medications has seen a significant expansion in modern years. It’s projected to climb from $2.87 billion in 2024 to $4.21 billion in 2025, indicating a compound annual growth rate (CAGR) of 46.6%. The surge during the historical period is due to factors such as soaring obesity rates, lifestyle modifications, heightened awareness and education, early detection of health issues, and an increase in healthcare spending.
Anticipated to experience steady expansion within the next few years, there is a forecast for the weight loss drugs market to reach an estimated $16.82 billion by 2029. The market will bolster at a compound annual growth rate (CAGR) of 41.4%. The growth rate throughout the forecasted period can be linked to a variety of factors, including the rise in the elderly population, social media’s impact, the surge in fitness and wellness inclination, cultural standards of beauty, and substantial investments by the pharmaceutical industry. Curated trends for the forecast period consist of technological innovations, a shift towards non-prescription alternatives, the integration of personalized medication, merging therapies, product evolution, and post-market monitoring.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13761&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Weight Loss Drugs Market?
The anticipated rise in obesity rates is forecasted to spur the expansion of the weight loss drugs market. The term ‘obesity rate’ refers to the percentage of a population with a body mass index (BMI) of 30 or above. Obesity management drugs are designed to facilitate weight loss by decreasing appetite, enhancing feelings of satisfaction, or inhibiting the absorption of nutrients. For example, in September 2023, data from the Centers for Disease Control and Prevention, a US governmental agency, revealed that the prevalence of adult obesity surpassed 35% in 19 states in 2021 and in 22 states the following year. Moreover, as of 2022, the adult obesity prevalence was at or above 35%. In addition, in March 2023, according to the World Obesity Federation, a non-profit organization based in the UK, it was projected that by 2035, over 4 billion people are likely to be obese. Thus, the escalating obesity rates are fueling the advancement of the weight loss drugs market.
Which Primary Segments of the Weight Loss Drugs Market Are Driving Growth and Industry Transformations?
The weight loss drugsmarket covered in this report is segmented –
1) By Type: Liquid; Tablets; Capsules
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By Application: Weight-Reducing Aid; Fat Absorption Inhibitors; Metabolic Boosters
Subsegments:
1) By Liquid: Syrups; Solutions; Suspensions
2) By Tablets: Immediate-Release Tablets; Extended-Release Tablets
3) By Capsules: Hard Capsules; Softgel Capsules
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13761&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Weight Loss Drugs Market?# Market?
North America was the largest region in the Weight Loss Drugs market in 2024. The regions covered in the weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Weight Loss Drugs Market?
Leading firms in the weight loss drug sector are pushing innovation and have introduced new products such as Zepbound (tirzepatide) injection in an attempt to meet patient needs more effectively. Zepbound is a GIP and GLP-1 receptor agonist, and is applied once per week. The US pharmaceutical company, Eli Lilly and Company, gained FDA approval for tirzepatide injection (Zepbound) for long-term weight management in adults with obesity or excessive weight and at least one weight-related condition in November 2023. Zepbound stands as a highly promising commercially viable drug since it is presently the only FDA-approved obesity treatment which triggers both GIP and GLP-1 receptors.
View the full report here:
https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report
What Parameters Are Used to Define the Weight Loss Drugs Market?
Weight loss drugs are pharmaceutical substances that help reduce appetite and food cravings, leading to a decrease in calorie intake and weight loss. These drugs are FDA-approved and are prescribed by doctors to treat obesity or overweight individuals who have other weight-related medical conditions such as high blood pressure, type 2 diabetes, or high cholesterol.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13761
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model